Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4642 + Nimotuzumab + Chemotherapy in Borderline Resectable Pancreatic Cancer
NCT07240766Phase 2Recruiting
- Sponsor
- Zhejiang University
- Start
- Feb 2026
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-4642 in pancreatic cancer (PC), sponsored by Zhejiang University. Started Feb 2026; status: recruiting.
02
Drugs
HRS-4642
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07240766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07240766.